Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot
Tinea Pedis
Primary: Number of Participants With Complete Cure: Post Treatment (Day 17) — 0; 4 Participants
Phase 3 N=264 Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
Tinea Pedis · Athlete's Foot
Primary: Complete Cure — 63; 81; 19; 2 Participants
Phase 3 N=707 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
Tinea Pedis · Athlete's Foot
Primary: Percentage of Subjects With Complete Cure at Week 6. — 17.7; 7.1; 16.1; 3.1 percentage of subjects with complete cur — p=0.010
Phase 3 N=290 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis
Tinea Pedis
Primary: Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2) — 73; 10 participants
Phase 2 N=12 A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Tinea Pedis
Primary: Safety Evaluation Cohort 1 — 8; 0; 0; 0 Feet
Phase 3 N=860 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Tinea Pedis
Primary: Complete Cure of Interdigital Tinea Pedis — 26.0; 3.3 percentage of subjects — p=<0.025
Phase 3 N=133 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
Moderate to Severe Atopic Hand and Foot Dermatitis
Primary: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 — 16.7; 40.3 Percentage of participants — p==0.0030
Phase 3 N=855 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Tinea Pedis
Primary: Complete Cure of Interdigital Tinea Pedis — 16.8; 1.7 percentage of subjects — p=<0.025
N/A N=60 Metatarsal Phalangeal Joint Deformity Progression - R01
Diabetes Mellitus (DM)
Primary: Change in Metatarsal Phalangeal Joint Angle (Degrees) in People With Diabetes From Baseline and at a 3-year Period — 0.8; -0.1 degrees
Phase 4 N=19 Study Evaluating the Effect of Jublia on Dermatophytomas
Onychomycosis · Dermatophytosis
Primary: Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO) — 19 Participants
N/A N=20 Improving DFU Outcomes: Early Detection of Foot Ulcers Using Novel Technology
Diabetic Foot Ulcer
Primary: Adherence to Use of SmartMat — 6.4 number of foot scans/week
N/A N=99 Enhancing Diabetic Foot Education by Viewing Personal Plantar Pressures
Diabetes Mellitus · Diabetic Neuropathies · Foot Complications
Primary: Foot Care Behavior Score — 29; 36; 33; 42 Participants — p=0.0770
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm
Phase 3 N=831 Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
Tinea Pedis
Primary: Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population) — 89; 90…
N/A N=82 Development and Testing of a New Generation of Diabetic Footwear
Diabetes Complications · Diabetic Neuropathies
Primary: Postural Sway During Shod Standing — 4.3; 3.1 cm^2
Phase 2 N=50 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis
Tinea Pedis
Primary: Percentage of Subjects With Therapeutic Cure at 42 Days for All-analysis Population — 2; 1; 3; 0 Participants
Phase 3 N=40 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients
Onychomycosis
Primary: Primary Endpoint - Efficacy — 4 Participants
N/A N=30 Patient Specific 3D Printed Diabetic Insoles to Reduce Plantar Pressure
Diabetes
Primary: Plantar Pressure - Standard of Care — 202.71 kPa
N/A N=27 Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer
Diabetic Foot Ulcer · Diabetic Foot
Primary: Plantar Foot Temperature Changes in Regions-of-interest in Response to Walking — 0.758; 0.272 Absolute change in temperature degrees
Phase 3 N=139 PinPointe FootLaser for the Treatment of Onychomycosis
Infected Toenails · Onychomycosis
Primary: Nail Bed Clearing
N/A N=126 Light Therapy for Onychomycosis Study
Onychomycosis of Toenail
Primary: An Increase in Healthy New Nail Growth Free of Fungal Infection ("Clear Nail") at 12 Months Post-treatment — 5.9; 5.5 millimeters (mm)
Phase 2 N=135 A Study of Econazole Foam 1% in Athlete's Foot
Tinea Pedis · Athlete's Foot
Primary: Complete Cure Rate: Interdigital Disease — 9; 9; 1 Participants
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
N/A N=182 Less Infections for the Diabetic Foot
Diabetic Foot
Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants
Phase 3 N=876 Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
Tinea Pedis
Primary: Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure — 96; 81 Participants
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
N/A N=80 Polyurethane Foam on the Heel for Prevention in Children
Flat Foot · Pressure Ulcer
Primary: Heel Pressure Sores (Numbers of Participants With Heel Pressure Sores) — 17; 21 Participants
Phase 4 N=20 A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis
Hand Dermatitis
Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale